ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.
According to a cohort study using target trial emulation, older adults at higher risk for dementia are less likely to have a dementia diagnosis if they received a herpes zoster (shingles) vaccine.
A study has found that intravenous immune globulin (IVIG) reduces grade 2 infections by 67 percent in patients with chronic lymphocytic leukemia.
A study has found pediatric flu vaccines significantly reduce the number of childhood cases of influenza.
A study has found the combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, is successful in cutting the risk of skin cancer recurrence and death by 49 percent.
A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
According to multiple large observational studies, the risk of dementia is associated with eight routine adult vaccines: the shingles, respiratory syncytial virus, influenza, DTP (diphtheria, tetanus and pertussis), pneumococcal, hepatitis A, hepatitis B and typhoid vaccines.
Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies
Intravenous immune globulin (IVIG) improved clinical response rates in patients with autoimmune encephalitis (AE) who had inadequate response to steroid pulse therapy.